Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[2-[2-[(4-chlorophenyl)methoxy]ethylamino]ethyl]isoquinoline-5-sulfonamide is a synthetic small molecule belonging to the class of isoquinoline-5-sulfonic acid amides. This compound is identified as a potential inhibitor of Akt (Protein Kinase B), a crucial enzyme involved in cell survival, proliferation, and metabolism. By inhibiting Akt, the compound is hypothesized to exert antineoplastic and antiviral effects, making it a candidate for the treatment of various cancers and viral infections. Its mechanism of action suggests interference with pathways critical for disease progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[2-[2-[(4-chlorophenyl)methoxy]ethylamino]ethyl]isoquinoline-5-sulfonamide.